Get the Stockscreener App
5.85
4.10%
-0.25
After Hours:
5.79
-0.06
-1.03%
Personalis Inc stock is traded at $5.85, with a volume of 1.01M.
It is down -4.10% in the last 24 hours and up +28.01% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$6.10
Open:
$6.06
24h Volume:
1.01M
Relative Volume:
0.81
Market Cap:
$518.76M
Revenue:
$73.48M
Net Income/Loss:
$-108.30M
P/E Ratio:
-2.60
EPS:
-2.25
Net Cash Flow:
$-67.17M
1W Performance:
+11.64%
1M Performance:
+28.01%
6M Performance:
+53.14%
1Y Performance:
+2.09%
1-Day Range:
$5.68
$6.06
1-Week Range:
$5.21
$6.255
52-Week Range:
$2.8262
$7.79
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
5.85 | 477.97M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
479.46 | 179.95B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
190.05 | 137.90B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
641.14 | 51.04B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
123.24 | 35.19B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
187.22 | 31.26B | 15.70B | 1.24B | 2.01B | 6.91 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Personalis (NASDAQ:PSNL) Stock Price Up 6.5%What's Next? - MarketBeat
What earnings revisions data tells us about Personalis Inc.2025 Big Picture & Scalable Portfolio Growth Ideas - newser.com
HC Wainwright Reaffirms Buy Rating for Personalis (NASDAQ:PSNL) - MarketBeat
Is a relief rally coming for Personalis Inc. holdersEarnings Beat & High Accuracy Swing Trade Signals - Newser
Personalis Inc. stock trend outlook and recovery pathMarket Sentiment Report & Consistent Income Trade Recommendations - Newser
How to build a dashboard for Personalis Inc. stockQuarterly Portfolio Summary & Weekly High Potential Alerts - Newser
Trexquant Investment LP Raises Stock Position in Personalis, Inc. $PSNL - MarketBeat
Will Personalis Inc. bounce back from current supportJuly 2025 News Drivers & Weekly Breakout Opportunity Watchlist - Newser
Can Personalis Inc. recover in the next quarter2025 Year in Review & Fast Entry and Exit Trade Plans - Newser
Ranking Personalis Inc. among high performing stocks via toolsQuarterly Investment Review & Fast Moving Trade Plans - Newser
Custom watchlist performance reports with Personalis Inc.Portfolio Risk Summary & AI Powered Market Trend Analysis - Newser
Is Personalis Inc. stock poised for growth2025 Dividend Review & Reliable Breakout Stock Forecasts - Newser
Personalis' MRD Breakthrough Potential: Why I Hold Until Reimbursement Clarity Emerges - Seeking Alpha
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test - Business Wire
Recent Uptick Might Appease Personalis, Inc. (NASDAQ:PSNL) Institutional Owners After Losing 6.6% Over the Past Year - 富途牛牛
Is Personalis (NASDAQ:PSNL) A Risky Investment? - simplywall.st
Advanced analytics toolkit walkthrough for Personalis Inc.Weekly Risk Summary & Daily Price Action Insights - Newser
Signal strength of Personalis Inc. stock in tech scannersTrade Ideas & Technical Pattern Based Signals - Newser
Can a trend reversal in Personalis Inc. lead to recoveryTreasury Yields & Weekly Chart Analysis and Trade Guides - Newser
Is Personalis Inc. stock ready for a breakoutPortfolio Risk Summary & Real-Time Market Trend Scan - Newser
Momentum divergence signals in Personalis Inc. chartWeekly Profit Report & Weekly Breakout Opportunity Watchlist - Newser
H.C. Wainwright reiterates Buy rating on Personalis stock at $8.50 By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy rating on Personalis stock at $8.50 - Investing.com
PSNL: HC Wainwright Reiterates 'Buy' Rating and Maintains Price Target | PSNL Stock News - GuruFocus
What recovery options are there for Personalis Inc.Portfolio Profit Report & Smart Allocation Stock Tips - Newser
What are Personalis Inc.’s recent SEC filings showingEarnings Recap Report & Smart Money Movement Alerts - beatles.ru
Can Personalis Inc. expand its profit marginsJuly 2025 Intraday Action & Stepwise Swing Trade Plans - 강소기업뉴스
Is Personalis Inc. showing signs of accumulation2025 Trading Recap & Capital Efficiency Focused Ideas - Newser
Will Personalis Inc. stock go up in YEARQuarterly Earnings Summary & AI Driven Stock Price Forecasts - خودرو بانک
Personalis, Inc. shares rise 1.38% intraday after BioNTech's breast cancer trial win. - AInvest
Chart based exit strategy for Personalis Inc.Portfolio Performance Summary & Free Long-Term Investment Growth Plans - Newser
Can Personalis Inc. benefit from deglobalizationJuly 2025 Patterns & Growth Oriented Trade Recommendations - خودرو بانک
Long term hold vs stop loss in Personalis Inc.July 2025 Patterns & AI Powered Market Entry Strategies - Newser
Does Personalis Inc. have declining or rising EPSTrade Volume Report & Growth-Oriented Investment Plans - خودرو بانک
Personalis MRD test predicts outcomes in lung cancer trial By Investing.com - Investing.com Australia
Personalis, Inc. shares rise 1.03% premarket after announcing new data from AstraZeneca phase 3 clinical trial. - AInvest
Is Personalis Inc. stock a good pick for beginnersEarnings Recap Summary & Weekly Hot Stock Watchlists - خودرو بانک
Using R and stats models for Personalis Inc. forecasting2025 Top Gainers & AI Enhanced Execution Alerts - Newser
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing - biospace.com
Will Personalis Inc. stock go up soonWeekly Earnings Recap & Verified Short-Term Plans - Newser
Personalis and the MRD Testing Revolution in Early-Stage Lung Cancer - AInvest
Personalis announces new data from neoadjuvant lung cancer trial - MarketScreener
Personalis reports data from lung cancer trial (PSNL:NASDAQ) - Seeking Alpha
Personalis MRD test predicts outcomes in lung cancer trial - Investing.com
Is Personalis Inc. reversing from oversold territoryTrade Performance Summary & Detailed Earnings Play Alerts - Newser
Is Personalis Inc. benefiting from interest rate changes2025 Market Trends & Reliable Price Action Trade Plans - خودرو بانک
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Personalis Inc Stock (PSNL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tachibana Aaron | CFO AND COO |
Jul 28 '25 |
Sale |
6.57 |
641 |
4,211 |
164,458 |
| Tachibana Aaron | CFO AND COO |
May 16 '25 |
Sale |
4.95 |
1,291 |
6,390 |
165,099 |
| Moore Stephen Michael | SVP and Chief Legal Officer |
May 16 '25 |
Sale |
4.95 |
1,675 |
8,291 |
64,200 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
May 16 '25 |
Sale |
4.95 |
910 |
4,504 |
124,957 |
| Tachibana Aaron | CFO AND COO |
Jan 28 '25 |
Sale |
5.79 |
708 |
4,099 |
166,390 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Jan 28 '25 |
Sale |
5.79 |
519 |
3,005 |
123,367 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Dec 16 '24 |
Sale |
3.82 |
4,834 |
18,466 |
123,886 |
| Moore Stephen Michael | SVP and Chief Legal Officer |
Dec 16 '24 |
Sale |
3.82 |
1,513 |
5,780 |
65,875 |
| Tachibana Aaron | CFO AND COO |
Dec 16 '24 |
Sale |
3.82 |
6,865 |
26,224 |
167,098 |
| Tachibana Aaron | CFO AND COO |
Nov 18 '24 |
Sale |
3.79 |
1,307 |
4,954 |
173,963 |
2.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):